Currently, there are 635.24M common shares owned by the public and among those 635.23M shares have been available to trade.
The company’s stock has a 5-day price change of 2.20% and -14.10% over the past three months. GMAB shares are trading -35.71% year to date (YTD), with the 12-month market performance down to -34.89% lower. It has a 12-month low price of $19.85 and touched a high of $32.88 over the same period. GMAB has an average intraday trading volume of 1.27 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -2.59%, -5.81%, and -21.46% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Genmab ADR (NASDAQ: GMAB) shares accounts for 8.28% of the company’s 635.24M shares outstanding.
It has a market capitalization of $13.00B and a beta (3y monthly) value of 0.97. The stock’s trailing 12-month PE ratio is 19.72, while the earnings-per-share (ttm) stands at $1.04. The company has a PEG of 0.79 and a Quick Ratio of 5.15 with the debt-to-equity ratio at 0.03. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.18% over the week and 1.68% over the month.
Earnings per share for the fiscal year are expected to increase by 28.19%, and 10.36% over the next financial year. EPS should grow at an annualized rate of 24.96% over the next five years, compared to 20.52% over the past 5-year period.
Morgan Stanley coverage for the Genmab ADR (GMAB) stock in a research note released on September 04, 2024 offered a Equal-Weight rating with a price target of $31. BMO Capital Markets on their part issued Outperform rating on February 23, 2024.
